Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SYH2072 in uncontrolled hypertension despite at least 2 antihypertensive drugs
CTR20264013Phase 2Active
- Sponsor
- Yishi Pharma
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SYH2072 in hypertension (HTN), resistant hypertension (RH), sponsored by Yishi Pharma. Started Oct 2026; status: active.
02
Drugs
SYH2072
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20264013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264013.